$ALVR News
Last published 3mo ago
- 3mo agoKLRSALVRKLRS: Abbott Cooper PLLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. (Formerly Allovir, Inc.) StockholdersGlobeNewswireSTAMFORD, Conn., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating potential legal claims on behalf of stockholders of Kalaris Therapeutics, Inc. (NASDAQ:KLRS), formerly AlloVir, Inc.
- 1y agoALVRKalaris and AlloVir Announce Stockholder Approval of MergerGlobeNewswirePALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. ("Kalaris"), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of
- 2y agoALVRAlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the RetinaGlobeNewswireKalaris is a clinical-stage biopharmaceutical company founded by Samsara BioCapital and focused on development of TH103, a novel, differentiated and potentially transformative therapy for patients with neovascular and
- 2y agoALVRKuehn Law Encourages Investors of AlloVir, Inc. to Contact Law FirmGlobeNewswireNEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of AlloVir, Inc. (NASDAQ:ALVR) breached their fiduciary duties to
- 2y agoALVRSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AllovirPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AlloVir, Inc. ("AlloVir" or the "Company")...
- 2y agoALVRINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AllovirGlobeNewswireNEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AlloVir, Inc. ("AlloVir" or the "Company") (NASDAQ:ALVR) and
- 2y agoALVRALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
- 2y agoALVRALLOVIR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
- 2y agoALVRALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AlloVir, Inc. ("AlloVir" or the "Company")...
- 2y agoALVRALLOVIR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
- 2y agoALVRALLOVIR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
- 2y agoALVRALLOVIR INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their OptionsPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AlloVir, Inc. ("AlloVir" or the "Company")...
- 2y agoALVRALLOVIR SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In AlloVir To Contact Him Directly To Discuss Their OptionsGlobeNewswireIf you suffered losses exceeding $25,000 investing in AlloVir stock or options between March 22, 2022 and December 21, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson
- 2y agoALVRAlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell TherapyGlobeNewswireCompany to discontinue its three Phase 3 posoleucel studies following separate, pre-planned DSMB futility analyses concluding the studies were unlikely to meet their primary endpoints; no safety concerns identified
- 2y agoALVRAlloVir to Present at the Piper Sandler 35th Annual Healthcare ConferenceBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler
- 3y agoALVRAlloVir Reports Third Quarter 2023 Financial ResultsBusiness Wire-- Posoleucel, a highly innovative off-the-shelf, multi-virus-specific investigational T cell therapy, continues to advance in three distinct, Phase 3, first-to-market indications in immunocompromised patients --
- 3y agoALVRAlloVir to Present at Upcoming Investor ConferencesBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in the following upcoming investor
- 3y agoALVRAlloVir Reports Second Quarter 2023 Financial ResultsBusiness WireCompany's three Phase 3 global registrational trials for its allogeneic, off-the-shelf, virus-specific T cell therapy, posoleucel, in three distinct, first-to-market indications in allo-HCT patients continue to
- 3y agoALVRAlloVir Announces Pricing of Public Offering of Common StockBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late clinical-stage cell therapy company, today announced the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $3.75 per
- 3y agoALVRAlloVir Announces Proposed Public Offering of Common StockBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late clinical-stage cell therapy company, today announced that it has commenced a proposed underwritten public offering of $75.0 million of shares of its common stock. AlloVir also intends
- 3y agoALVRAlloVir Presents Positive Final Results From A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of BK Infection in Kidney Transplant Recipients at the American Transplant Congress (ATC 2023)Business WirePosoleucel demonstrated clinically meaningful reductions in BK viral load as compared to placebo with the greatest antiviral activity seen among patients with higher viral loads and those who received more frequent
- 3y agoALVRAlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial OfficerBusiness Wire- Industry veteran brings more than 25 years of global commercial leadership and cell therapy expertise to AlloVir to build out company's commercial strategy and capabilities - AlloVir (NASDAQ:ALVR), a
- 3y agoALVRAlloVir Reports First Quarter 2023 Financial ResultsBusiness WireCompany's three posoleucel Phase 3 global registrational trials for three distinct, first-to-market indications continue to enroll with data readouts on track for 2024 Positive results from a randomized, double-blind,
- 3y agoALVRAlloVir to Present at the BofA Securities 2023 Health Care ConferenceBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, announced today that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the BofA Securities
- 3y agoALVRAlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023Business WireDay 400 non-relapse mortality was 0% Previously reported data from the 14-week primary endpoint showed low rates of clinically significant viral infections and diseases in this high-risk patient population despite the
- 3y agoALVRAlloVir Appoints Derek Adams, Ph.D., to Board of DirectorsBusiness WireAlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T cell immunotherapy company, today announced the appointment of Derek Adams, Ph.D., to its Board of Directors, effective March 1, 2023. Dr. Adams brings more than
- 3y agoALVRAlloVir Reports Full-Year 2022 Financial Results and 2023 OutlookBusiness WireCompletion of enrollment of all three posoleucel Phase 3 registrational trials for three distinct, first-to-market indications anticipated by end of 2023 and data readouts in 2024 Positive final results from
- 3y agoALVRAlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK ViremiaBusiness WireRepeat administration of posoleucel was generally well tolerated, with balanced safety across posoleucel dosing groups and placebo In Week 24 efficacy analysis, 39% (15/38) of patients who received posoleucel
- 3y agoALVRAlloVir to Participate in the SVB Securities Global Biopharma ConferenceBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage, allogeneic T-cell immunotherapy company, today announced that Chief Executive Officer Diana Brainard, M.D., will participate in a fireside chat at the SVB Securities
- 3y agoALVRAlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023Business WirePositive final posoleucel Phase 2 clinical data presented at ASH 2022 underscore potential as multi-virus prevention therapy and support ongoing global Phase 3 registration trial Completion of enrollment of all three
- 3y agoALVRAlloVir to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare
- 3y agoALVRAlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and ExpositionBusiness Wire23 of 26 (88%) patients remained free of clinically significant infections caused by any of six common viruses that posoleucel targets through the Week 14 primary endpoint 3 of 26 (12%) patients had clinically
- 3y agoALVRAlloVir to Participate in the Piper Sandler 34th Annual Healthcare ConferenceBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Piper Sandler
- 4y agoALVRFinal Data from AlloVir's Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual MeetingBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that final data from the Phase 2 study of posoleucel for the prevention of clinically significant infections or
- 4y agoALVRAlloVir Reports Third Quarter 2022 Financial ResultsBusiness WirePosoleucel Continues to Advance in Three Ongoing Multi-National Phase 3 Registrational Trials Final Data Presentation from Posoleucel Phase 2 Multi-Virus Prevention Study by Year-End Company to Host Investor Webcast
- 4y agoALVRAlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceBusiness WireAlloVir, Inc. (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Confe
- 4y agoALVRAlloVir Reports Second Quarter 2022 Financial ResultsBusiness WireThree Phase 3 Posoleucel Registrational Trials Continue to Expand Globally, Enrolling Patients in the U.S., Europe and Asia Company Is On Track to Release Final Results of Posoleucel Phase 2 Multi-Virus Prevention Study at Year-End and Topline Result
- 4y agoALVRGILDAlloVir Announces $126.6 Million Registered Direct OfferingBusiness WireProceeds Support the Completion of Three Global Phase 3 Registrational Trials for Posoleucel and Global Regulatory Filings AlloVir, Inc. (NASDAQ:ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered
- 4y agoALVRAlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant RecipientsBusiness WirePhase 2 study completed enrollment ahead of schedule Posoleucel well-tolerated with no cases of graft rejection observed to date Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 r
- 4y agoALVRAlloVir Reports First Quarter 2022 Financial ResultsBusiness WireInitiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention ind
- 4y agoALVRIOSEVSNOW+1Thinking about buying stock in Allovir, Sono Group, Ion Geophysical, Toughbuilt, or Snowflake?PR NewswireNEW YORK, April 20, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ALVR, SEV, IO, TBLT, and SNOW. To
- 4y agoALVRFDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for Prevention of Multiple Life-Threatening Infections from Six Viruses in Allogeneic Hematopoietic Cell Transplant PatientsBusiness WirePosoleucel's third RMAT designation marks an unprecedented regulatory distinction among cell and gene therapies Global Phase 3 multi-virus prevention trial initiated in March 2022 and is enrolling patients AlloVir (NASDAQ:ALVR), a late clinical-
- 4y agoALVRStudy of Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant - NCT05305040ClinicalTrials.govNumber of clinically significant infections or episodes of end-organ disease, Number of clinically significant infections or episodes of end-organ disease due to each virus, Mean area under the curve (AUC) viral load, (and 2 more...)
- 4y agoALVRAlloVir Appoints Shawn Tomasello to Its Board of DirectorsBusiness WireAlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commerci
- 4y agoALVRAlloVir Initiates Global Phase 3 Registrational Study of Posoleucel for Prevention of Life-Threatening Viral Infections from Six Common Viruses in High-Risk, Allogeneic Hematopoietic Cell Transplant PatientsBusiness WireUpdated, preliminary Phase 2 data presented at EBMT Annual Meeting continue to demonstrate substantial reduction in the expected rate of clinically significant infections with posoleucel therapy 21 of 24 patients were free of clinically significant i
- 4y agoALVRAlloVir to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceBusiness WireAlloVir (NASDAQ:ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on
- 4y agoALVRAlloVir Reports Full-Year 2021 Financial Results and 2022 OutlookBusiness WireThree ongoing Phase 3 registrational studies of posoleucel expected in 2022, targeting treatment and prevention indications with no approved therapies Expanded enrollment in Phase 2 proof-of-concept study of posoleucel for the preemptive treatment of
- 4y agoALVRFDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell TransplantationBusiness WireTreatment of AdV infection is posoleucel's second potential indication to receive RMAT designation Phase 3 registrational study of posoleucel for AdV treatment is now open for enrollment Proof-of-concept study of ALVR106 for the treatment of multi
- 4y agoALVRPosoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation - NCT05179057ClinicalTrials.govProportion of participants with undetectable viremia (less than lower limit of quantitation [LLOQ]) at Day 29, Incidence and severity of adverse events (AEs), including AE's of special interest (AESIs), Incidence and severity of acute GVHD during the study, (and 5 more...)
- 4y agoALVRAlloVir to Present at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness WireAlloVir (NASDAQ:ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced that Diana Brainard, M.D., Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022, at 4